PubMed · 8903856
Beta-2-microglobulin-associated amyloidosis.
Abstract
beta2-Microglobulin-associated amyloidosis has emerged as a major complication of long-term renal replacement therapy. The syndrome is confined to those patients on nontransplant modes of therapy. It does not occur in patients with a functioning renal transplant or, if already present, it does not progress any further in such patients. In the population of ESRD patients on dialysis, beta2-microglobulin-associated amyloidosis affects most patients treated for more than 15 years and is a cause of significant morbidity and in rare cases even mortality. The present review, which is based on the presentation of a typical case, discusses the current knowledge on the pathogenesis, clinical manifestations, diagnosis, prevention and therapy of beta2-microglobulin-associated amyloidosis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
J Floege, G Ehlerding. 1996. Beta-2-microglobulin-associated amyloidosis.. https://doi.org/10.1159/000188801
Cite the original work for its findings. Save a collection to share your selection of sources.